drugset / Trial / NCT04040621

Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

NCT04040621

Phase 1 Terminated 4 enrolled Pfizer AbbVie · collab
NaSingle-groupOpen-labelBasic science

Summary

This is a multicenter, multinational, open label single dose pharmacokinetic (PK) study enrolling at least 32 subjects. The study aims to characterize the pharmacokinetics (PK) of a single intravenous dose of CAZ AVI in pediatric subjects aged 3 months to less than 18 years who are receiving systemic antibiotic therapy for suspected or confirmed nosocomial pneumonia, including ventilator associated pneumonia.

Timeline

Start
2020-06-15
Primary completion
2021-04-09
Completion
2021-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftazidime-avibactam Other / unclassified Intravenous

Indications

No indication recorded.